Compare Samsara Inc (IOT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Samsara Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Samsara Inc trades at $39.06 (market cap $23.49B), while State Street SPDR S&P Biotech ETF trades at $158.84. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Samsara Inc nearer its low. Which is the better fit depends on your goals.
| IOT | XBI | |
|---|---|---|
Market Cap | $23.49B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $45.22 | $164.28 |
52-Week Low | $24.25 | $86.92 |
Enterprise Value | $22.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Samsara (IOT) trades at $39.11, down 1.88% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company shows impressive revenue growth, projecting $1.7B for 2026 with a positive net income turnaround to $58M. Recent earnings beats and a 'Moderate Buy' analyst consensus with a $44.50 price target highlight investor confidence in the Connected Operations Platform strategy.
Outlook remains positive with 36.9% upside potential to consensus targets, though elevated P/E ratio of 403.2 and negative 2025 EBITDA pose valuation risks. Key catalysts include continued AI adoption in physical operations and September earnings report, while competition and execution on growth investments represent primary challenges.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
